|1.||Leopold, Lance: 5 articles (12/2012 - 06/2008)|
|2.||Kisim, Asli: 3 articles (06/2013 - 10/2010)|
|3.||Uzunoglu, Selim: 3 articles (06/2013 - 10/2010)|
|4.||Atmaca, Harika: 3 articles (06/2013 - 10/2010)|
|5.||Karaca, Burcak: 3 articles (06/2013 - 10/2010)|
|6.||Uslu, Ruchan: 3 articles (06/2013 - 10/2010)|
|7.||Sezgin, Canfeza: 3 articles (06/2013 - 10/2010)|
|8.||Luo, Hao: 2 articles (01/2015 - 01/2014)|
|9.||Ren, Tao: 2 articles (01/2015 - 01/2014)|
|10.||Li, Mengxia: 2 articles (01/2015 - 01/2014)|
|1.||Prostatic Neoplasms (Prostate Cancer)
05/01/2009 - "An open-label, multicenter, phase I/II study of single-agent AT-101 in men with castrate-resistant prostate cancer."
08/01/2010 - "These data suggest that combination therapy of AT-101 and ADT may further delay the onset of AI disease, resulting in prolonged progression-free survival of prostate cancer patients."
05/01/2009 - "In this multi-institution phase I/II trial, we evaluated the safety and efficacy of single-agent AT-101, in men with chemotherapy naïve, castrate-resistant prostate cancer (CRPC). "
12/01/2007 - "We conclude that AT-101 in combination with surgical castration delays the onset of androgen-independent prostate cancer in vivo by disrupting the antiapoptotic activity of Bcl-2 upregulation during the transition to androgen independence. "
12/01/2007 - "AT-101 (15 mg/kg, per os (p.o.) 5 days/week) in combination with surgical castration delayed the onset of androgen-independent prostate cancer growth in vivo. "
|2.||Small Cell Lung Carcinoma (Small Cell Lung Cancer)
10/01/2011 - "We studied the efficacy of AT-101 in patients with recurrent chemosensitive extensive-stage small cell lung cancer (SCLC). "
10/01/2010 - "AT-101 is an oral, pan Bcl-2 family protein inhibitor that has demonstrated activity in small cell lung cancer (SCLC) models. "
10/01/2010 - "Phase I/II study of AT-101 with topotecan in relapsed and refractory small cell lung cancer."
10/01/2011 - "A phase II study of AT-101 (Gossypol) in chemotherapy-sensitive recurrent extensive-stage small cell lung cancer."
04/01/2014 - "A phase I, dose-escalation study of AT-101 with cisplatin and etoposide was conducted to determine the maximum tolerated dose (MTD)/recommended phase 2 dose (RP2D), safety and pharmacokinetics in patients with advanced solid tumors, with an expanded cohort in patients with extensive-stage small cell lung cancer (ES-SCLC) to assess preliminary activity. "
05/01/2008 - "AT-101 was not only cytotoxic to conventional multiple myeloma cell lines, but was also effective against drug-resistant cell lines and primary multiple myeloma patient cells. "
12/01/2009 - "This study was aimed to investigate the apoptosis effect of gossypol acetic acid on classic human multiple myeloma RPMI8226 cell line in vitro and its mechanism. "
12/01/2009 - "It is concluded that the gossypol acetic acid can selectively induce proliferation inhibition and apoptosis of multiple myeloma RPMI8226 cells with a smaller dose."
12/01/2009 - "[Apoptosis of multiple myeloma cells induced by gossypol acetic acid in vitro and its mechanism]."
05/01/2008 - "These data suggest that the activity of AT-101 may be highly relevant to multiple myeloma disease biology and may represent an option for treatment of patients with this disease."
|4.||Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung)
05/01/2010 - "AT-101, a pan-Bcl-2 inhibitor, leads to radiosensitization of non-small cell lung cancer."
01/01/2014 - "In conclusion, AT-101 enhances the sensitivity of A549 cells to CDDP in vitro and in vivo through the inhibition of APE1-mediated IL-6/STAT3 signaling activation, providing a rationale for the combined use of AT-101 and CDDP in non-small cell lung cancer chemotherapy. "
01/01/2015 - "AT-101 is a BH3 mimetic and pan-Bcl-2 inhibitor that has shown potent anticancer activity in non-small-cell lung cancer (NSCLC) in murine models, but failed to show clinical efficacy when used in combination with docetaxel in NSCLC patients. "
01/01/2015 - "Small-molecule BH3 mimetic and pan-Bcl-2 inhibitor AT-101 enhances the antitumor efficacy of cisplatin through inhibition of APE1 repair and redox activity in non-small-cell lung cancer."
01/01/2014 - "The present study aimed to examine whether AT-101 could increase the sensitivity of non-small cell lung cancer A549 cells to cisplatin (CDDP) and the underlying mechanisms. "
|5.||Head and Neck Neoplasms (Head and Neck Cancer)
01/01/2015 - "Targeting anti-apoptotic Bcl-2 by AT-101 to increase radiation efficacy: data from in vitro and clinical pharmacokinetic studies in head and neck cancer."
07/01/2013 - "Small molecule inhibitors such as AT-101 (a BH3-mimetic drug) have been developed to inhibit the antiapoptotic activity of Bcl-2 proteins, which proved effective in restoring radio- and chemo-sensitivity in head and neck cancer cells. "
07/01/2013 - "Results indicate the therapeutic benefit of combining siRNA-mediated knockdown of antiapoptotic Bcl-2 protein expression with low doses of AT-101 for inhibiting the growth of head and neck cancer cells. "
|4.||Proteins (Proteins, Gene)
|8.||DNA (Deoxyribonucleic Acid)
|9.||Small Interfering RNA (siRNA)
|10.||Etoposide (VP 16)
|1.||Drug Therapy (Chemotherapy)
|4.||Heterologous Transplantation (Xenotransplantation)